成人急性淋巴细胞白血病的新兴药物治疗方法。
Emerging pharmacotherapies for adult patients with acute lymphoblastic leukemia.
机构信息
Department of Hematology, Hillingdon Hospital, Pield Heath Road, Uxbridge, Middlesex, UB8 3NN.
出版信息
Clin Med Insights Oncol. 2012;6:85-100. doi: 10.4137/CMO.S7262. Epub 2012 Jan 22.
Abstract
Acute lymphoblastic leukemia (ALL) treatment regimes are amongst the longest, most intensive and complex used in hematooncology. Despite this, while treatment of pediatric ALL is a success story, we are far from being able to ensure a durable response in adult ALL. This is not due to failure of induction therapy as a complete remission (CR) is achieved in over 90% of patients. However the challenge remains in ensuring a sustained remission. Furthermore in the face of relapsed disease, salvage therapies currently offer a poor chance of a good outcome. This article reviews the novel agents which show the most promise in the treatment of adult ALL.
摘要
急性淋巴细胞白血病（ALL）的治疗方案是血液肿瘤学中最长、最密集和最复杂的治疗方案之一。尽管如此，尽管儿童 ALL 的治疗取得了成功，但我们远未能够确保成人 ALL 能够持久缓解。这并不是因为诱导治疗失败，因为超过 90%的患者达到完全缓解（CR）。然而，挑战仍然在于确保持续缓解。此外，面对复发疾病，目前的挽救治疗提供良好结局的机会很差。本文综述了在成人 ALL 治疗中最有前途的新型药物。
相似文献
1
Emerging pharmacotherapies for adult patients with acute lymphoblastic leukemia.成人急性淋巴细胞白血病的新兴药物治疗方法。
Clin Med Insights Oncol. 2012;6:85-100. doi: 10.4137/CMO.S7262. Epub 2012 Jan 22.
2
3
Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy.原发性难治性和复发性成人急性淋巴细胞白血病：特征、治疗结果及挽救治疗的预后
Cancer. 1999 Oct 1;86(7):1216-30. doi: 10.1002/(sici)1097-0142(19991001)86:7<1216::aid-cncr17>3.0.co;2-o.
4
Feasible outcome of blinatumomab followed by allogeneic hematopoietic cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.费城染色体阴性的成人急性淋巴细胞白血病一线挽救后接受blinatumomab 序贯异基因造血干细胞移植的可行性结果。
Cancer Med. 2019 Dec;8(18):7650-7659. doi: 10.1002/cam4.2680. Epub 2019 Nov 5.
5
Salvage therapy for children with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.复发或难治性费城染色体阳性急性淋巴细胞白血病患儿的挽救治疗
Pediatr Blood Cancer. 2017 Aug;64(8). doi: 10.1002/pbc.26423. Epub 2017 Jan 13.
6
FLAG/FLAG-IDA regimen for children with relapsed/refractory acute leukemia in the era of targeted novel therapies.在靶向新型疗法时代，用于复发/难治性急性白血病患儿的FLAG/FLAG-IDA方案
J Oncol Pharm Pract. 2019 Dec;25(8):1831-1838. doi: 10.1177/1078155218817816. Epub 2018 Dec 5.
7
Treatment of children with relapsed and refractory acute lymphoblastic leukemia with mitoxantrone, vincristine, pegaspargase, dexamethasone, and bortezomib.米托蒽醌、长春新碱、培门冬酶、地塞米松和硼替佐米治疗复发/难治性儿童急性淋巴细胞白血病。
Pediatr Blood Cancer. 2020 Mar;67(3):e28062. doi: 10.1002/pbc.28062. Epub 2019 Nov 14.
8
Teniposide (VM-26) and continuous infusion cytosine arabinoside for initial induction failure in childhood acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.替尼泊苷（VM - 26）与持续输注阿糖胞苷用于儿童急性淋巴细胞白血病初始诱导失败的治疗。一项儿科肿瘤学组的试点研究。
Cancer. 1990 Oct 15;66(8):1671-7. doi: 10.1002/1097-0142(19901015)66:8<1671::aid-cncr2820660803>3.0.co;2-e.
9
Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation.复发性成人急性淋巴细胞白血病的预后取决于挽救化疗的反应、预后因素以及干细胞移植的情况。
Blood. 2012 Sep 6;120(10):2032-41. doi: 10.1182/blood-2011-12-399287. Epub 2012 Apr 4.
10
Hematopoietic stem cell transplantation following unsuccessful salvage treatment for relapsed acute lymphoblastic leukemia in children.儿童复发性急性淋巴细胞白血病挽救治疗失败后的造血干细胞移植。
Pediatr Blood Cancer. 2015 Apr;62(4):674-9. doi: 10.1002/pbc.25353. Epub 2014 Dec 24.
引用本文的文献
1
Sorafenib inhibits therapeutic induction of necroptosis in acute leukemia cells.索拉非尼抑制急性白血病细胞中坏死性凋亡的治疗诱导。
Oncotarget. 2017 Aug 4;8(40):68208-68220. doi: 10.18632/oncotarget.19919. eCollection 2017 Sep 15.
2
Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults.成人复发性/难治性急性淋巴细胞白血病的治疗
Curr Oncol Rep. 2016 Jun;18(6):39. doi: 10.1007/s11912-016-0519-8.
3
Histone acetylation: novel target for the treatment of acute lymphoblastic leukemia.组蛋白乙酰化：急性淋巴细胞白血病治疗的新靶点。
Clin Epigenetics. 2015 Nov 4;7:117. doi: 10.1186/s13148-015-0151-8. eCollection 2015.
本文引用的文献
1
Targeting epigenetics through histone deacetylase inhibitors in acute lymphoblastic leukemia.通过组蛋白去乙酰化酶抑制剂靶向治疗急性淋巴细胞白血病的表观遗传学。
Curr Cancer Drug Targets. 2011 Sep;11(7):882-93. doi: 10.2174/156800911796798922.
2
A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia.一项抗 CD19 和抗 CD22 免疫毒素（Combotox）联合治疗难治性 B 系急性淋巴细胞白血病成人患者的 I 期研究。
Br J Haematol. 2011 Aug;154(4):471-6. doi: 10.1111/j.1365-2141.2011.08762.x. Epub 2011 Jul 7.
3
In vitro efficacy of forodesine and nelarabine (ara-G) in pediatric leukemia.体外研究氟达拉滨和奈拉滨（ara-G）在儿科白血病中的疗效。
Blood. 2011 Aug 25;118(8):2184-90. doi: 10.1182/blood-2011-02-337840. Epub 2011 Jul 5.
4
High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation.高剂量单药奈拉滨治疗复发 T 淋巴细胞白血病/淋巴瘤具有较高的活性，可作为后续干细胞移植的治愈选择。
Blood. 2011 Sep 29;118(13):3504-11. doi: 10.1182/blood-2011-01-329441. Epub 2011 Jun 28.
5
Early UK experience in the use of clofarabine in the treatment of relapsed and refractory paediatric acute lymphoblastic leukaemia.英国在使用克拉屈滨治疗复发/难治性儿童急性淋巴细胞白血病方面的早期经验。
Br J Haematol. 2011 Aug;154(4):482-5. doi: 10.1111/j.1365-2141.2011.08752.x. Epub 2011 Jun 21.
6
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.针对化疗耐药的 B 系急性淋巴细胞白血病患者微小残留病灶的 T 细胞结合抗体blinatumomab 的靶向治疗可带来高缓解率和延长无白血病生存。
J Clin Oncol. 2011 Jun 20;29(18):2493-8. doi: 10.1200/JCO.2010.32.7270. Epub 2011 May 16.
7
8
HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.HDAC 抑制剂增强了 BCR/ABL 激酶抑制剂 KW-2449 在体外和体内对伊马替尼敏感或耐药的 BCR/ABL+白血病细胞中的活性。
Clin Cancer Res. 2011 May 15;17(10):3219-32. doi: 10.1158/1078-0432.CCR-11-0234. Epub 2011 Apr 7.
9
Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors.靶向活性 mTOR 抑制原代白血病 T 细胞，并与细胞毒性药物和信号抑制剂协同作用。
Exp Hematol. 2011 Apr;39(4):457-472.e3. doi: 10.1016/j.exphem.2011.01.005. Epub 2011 Jan 26.
10
Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial.米托蒽醌对急性淋巴细胞白血病（ALL R3）首次复发儿童结局的影响：一项开放标签随机试验。
Lancet. 2010 Dec 11;376(9757):2009-17. doi: 10.1016/S0140-6736(10)62002-8. Epub 2010 Dec 3.
Zotero 插件